Search

• CAR-T cell therapy has shown significant clinical responses in malignancies like B-cell leukaemia and lymphoma. • There are is very little research and limited number (just 2) trials conducted on CAR T-cell therapy in the Indian subcontinent. This is a cause for concern, given the proven efficacy of the therapy. • High cost, technical requirements, funding challenges, and lack of a complex workforce are limiting factors for conducting CAR-T cell therapy clinical trials in India. [ABSTRACT FROM AUTHOR]

The ongoing COVID‐19 pandemic caused by SARS‐CoV‐2 is associated with high morbidity and mortality. This zoonotic virus has emerged in Wuhan of China in December 2019 from bats and pangolins probably and continuing the human‐to‐human transmission globally since last two years. As there is no efficient approved treatment, a number of vaccines were developed at an unprecedented speed to counter the pandemic. Moreover, vaccine hesitancy is observed that may be another possible reason for this never ending pandemic. In the meantime, several variants and mutations were identified and causing multiple waves globally. Now the safety and efficacy of these vaccines are debatable and recommended to determine whether vaccines are able to interrupt transmission of SARS‐CoV‐2 variant of concern (VOC). Moreover, the VOCs continue to emerge that appear more transmissible and less sensitive to virus‐specific immune responses. In this overview, we have highlighted various drugs and vaccines used to counter this pandemic along with their reported side effects. Moreover, the preliminary data for the novel VOC "Omicron" are discussed with the existing animal models. [ABSTRACT FROM AUTHOR]